Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson Pharmaceuticals, a specialty pharmaceutical company, has announced that its subsidiary, Watson Laboratories, Inc, has received final approval from the FDA on its abbreviated new drug application for bupropion hydrochloride extended-release tablets in the 150mg strength.
Subscribe to our email newsletter
Bupropion hydrochloride extended-release tablets are the generic equivalent to GlaxoSmithKline’s Wellbutrin XL product, which is indicated for the treatment of major depressive disorder. Watson intends to launch the product immediately.